Cargando…

The Amphibian Antimicrobial Peptide Temporin B Inhibits In Vitro Herpes Simplex Virus 1 Infection

The herpes simplex virus 1 (HSV-1) is widespread in the population, and in most cases its infection is asymptomatic. The currently available anti-HSV-1 drugs are acyclovir and its derivatives, although long-term therapy with these agents can lead to drug resistance. Thus, the discovery of novel anti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Marcocci, M. E., Amatore, D., Villa, S., Casciaro, B., Aimola, P., Franci, G., Grieco, P., Galdiero, M., Palamara, A. T., Mangoni, M. L., Nencioni, L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2018
Materias:	Antiviral Agents
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5923125/ https://www.ncbi.nlm.nih.gov/pubmed/29483113 http://dx.doi.org/10.1128/AAC.02367-17

Ejemplares similares

Broad-Spectrum Antiviral Activity of the Amphibian Antimicrobial Peptide Temporin L and Its Analogs
por: Zannella, Carla, et al.
Publicado: (2022)

Griffithsin and Carrageenan Combination To Target Herpes Simplex Virus 2 and Human Papillomavirus
por: Levendosky, Keith, et al.
Publicado: (2015)

The Inhibition of DNA Viruses by the Amphibian Antimicrobial Peptide Temporin G: A Virological Study Addressing HSV-1 and JPCyV
por: Marcocci, Maria Elena, et al.
Publicado: (2022)

Ilaprazole and Other Novel Prazole-Based Compounds That Bind Tsg101 Inhibit Viral Budding of Herpes Simplex Virus 1 and 2 and Human Immunodeficiency Virus from Cells
por: Leis, Jonathan, et al.
Publicado: (2021)

Antifungal Activity of the Frog Skin Peptide Temporin G and Its Effect on Candida albicans Virulence Factors
por: D’Auria, Felicia Diodata, et al.
Publicado: (2022)

Lausannevirus Encodes a Functional Dihydrofolate Reductase Susceptible to Proguanil
por: Mueller, L., et al.
Publicado: (2017)

Polymerase Activity, Protein-Protein Interaction, and Cellular Localization of the Usutu Virus NS5 Protein
por: Albentosa-González, L., et al.
Publicado: (2019)

Prophylactic Administration of the Monoclonal Antibody Adintrevimab Protects against SARS-CoV-2 in Hamster and Non-Human Primate Models of COVID-19
por: Zumbrun, Elizabeth E., et al.
Publicado: (2022)

Effect of Rifampin on the Single-Dose Pharmacokinetics of Oral Cabotegravir in Healthy Subjects
por: Ford, S. L., et al.
Publicado: (2017)

A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of V-7404 in Healthy Adult Volunteers
por: Kankam, Martin K., et al.
Publicado: (2021)

PTC725, an NS4B-Targeting Compound, Inhibits a Hepatitis C Virus Genotype 3 Replicon, as Predicted by Genome Sequence Analysis and Determined Experimentally
por: Graci, Jason D., et al.
Publicado: (2016)

Characterization of Influenza B Virus Variants with Reduced Neuraminidase Inhibitor Susceptibility
por: Farrukee, R., et al.
Publicado: (2018)

Emergence of Resistance in HIV-1 Integrase with Dolutegravir Treatment in a Pediatric Population from the IMPAACT P1093 Study
por: Vavro, Cindy, et al.
Publicado: (2022)

Moxidectin and Ivermectin Inhibit SARS-CoV-2 Replication in Vero E6 Cells but Not in Human Primary Bronchial Epithelial Cells
por: Dinesh Kumar, Nilima, et al.
Publicado: (2022)

Inhibition of Arenaviruses by Combinations of Orally Available Approved Drugs
por: Herring, Shawn, et al.
Publicado: (2021)

In Vitro Selection of Remdesivir-Resistant SARS-CoV-2 Demonstrates High Barrier to Resistance
por: Checkmahomed, Liva, et al.
Publicado: (2022)

Multipurpose Prevention Approaches with Antiretroviral-Based Formulations
por: Jean-Pierre, Ninochka, et al.
Publicado: (2016)

ATI-2173, a Novel Liver-Targeted Non-Chain-Terminating Nucleotide for Hepatitis B Virus Cure Regimens
por: Squires, Katherine E., et al.
Publicado: (2020)

Forgiveness of INSTI-Containing Regimens at Drug Concentrations Simulating Variable Adherence In Vitro
por: Acosta, Rima K., et al.
Publicado: (2022)

Safety and Pharmacokinetics of LHF-535, a Potential Treatment for Lassa Fever, in Healthy Adults
por: Amberg, Sean M., et al.
Publicado: (2022)

Antiviral Activity of Bictegravir (GS-9883), a Novel Potent HIV-1 Integrase Strand Transfer Inhibitor with an Improved Resistance Profile
por: Tsiang, Manuel, et al.
Publicado: (2016)

Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages
por: Sake, Svenja M., et al.
Publicado: (2022)

In Vitro Exposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles
por: Bowman, Emily R., et al.
Publicado: (2020)

A Subcutaneous Implant of Tenofovir Alafenamide Fumarate Causes Local Inflammation and Tissue Necrosis in Rabbits and Macaques
por: Su, Jonathan T., et al.
Publicado: (2020)

Extended Analysis of HIV Infection in Cisgender Men and Transgender Women Who Have Sex with Men Receiving Injectable Cabotegravir for HIV Prevention: HPTN 083
por: Marzinke, Mark A., et al.
Publicado: (2023)

Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir
por: Badri, Prajakta S., et al.
Publicado: (2015)

Characterization of a Novel Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B Virus Infection
por: Burdette, Dara, et al.
Publicado: (2022)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

Can We Improve Stavudine's Safety Profile in Children? Pharmacokinetics of Intracellular Stavudine Triphosphate with Reduced Dosing
por: Innes, Steve, et al.
Publicado: (2018)

Reciprocal Effects of Antiretroviral Drugs Used To Treat HIV Infection on the Fibroblast Growth Factor 21/β-Klotho System
por: Moure, Ricardo, et al.
Publicado: (2018)

Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production
por: Fintelman-Rodrigues, Natalia, et al.
Publicado: (2020)

Safety, Pharmacokinetics, and Antiviral Activity of a Novel HIV Antiviral, ABX464, in Treatment-Naive HIV-Infected Subjects in a Phase 2 Randomized, Controlled Study
por: Steens, Jean-Marc, et al.
Publicado: (2017)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men
por: Han, Kelong, et al.
Publicado: (2022)

Native Human Monoclonal Antibodies with Potent Cross-Lineage Neutralization of Influenza B Viruses
por: Vigil, Adam, et al.
Publicado: (2018)

Antiviral Properties of HIV-1 Capsid Inhibitor GSK878
por: Wang, Chunfu, et al.
Publicado: (2023)

Key Metabolic Enzymes Involved in Remdesivir Activation in Human Lung Cells
por: Li, Ruidong, et al.
Publicado: (2021)

Geneticin Stabilizes the Open Conformation of the 5′ Region of Hepatitis C Virus RNA and Inhibits Viral Replication
por: Ariza-Mateos, Ascensión, et al.
Publicado: (2016)

Human Safety, Tolerability, and Pharmacokinetics of Molnupiravir, a Novel Broad-Spectrum Oral Antiviral Agent with Activity against SARS-CoV-2
por: Painter, Wendy P., et al.
Publicado: (2021)

Integrase Inhibitor Resistance Mechanisms and Structural Characteristics in Antiretroviral Therapy-Experienced, Integrase Inhibitor-Naive Adults with HIV-1 Infection Treated with Dolutegravir plus Two Nucleoside Reverse Transcriptase Inhibitors in the DAWNING Study
por: Underwood, Mark, et al.
Publicado: (2022)

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Trial of MHAA4549A, a Monoclonal Antibody, plus Oseltamivir in Patients Hospitalized with Severe Influenza A Virus Infection
por: Lim, Jeremy J., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r283582jh0h9j44gdl4jkhl535